Holen Sie sich die Stockscreener-App
18.21
4.44%
0.775
Handel nachbörslich:
18.22
0.005
+0.03%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$17.44
Offen:
$17.75
24-Stunden-Volumen:
7.09M
Relative Volume:
0.85
Marktkapitalisierung:
$20.92B
Einnahmen:
$14.57B
Nettoeinkommen (Verlust:
$-296.50M
KGV:
-70.33
EPS:
-0.259
Netto-Cashflow:
$1.64B
1W Leistung:
+4.44%
1M Leistung:
+9.40%
6M Leistung:
+31.42%
1J Leistung:
+82.52%
1-Tages-Spanne:
$17.70
$18.23
1-Wochen-Bereich:
$17.18
$18.23
52-Wochen-Spanne:
$9.73
$18.43
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
18.21 | 20.92B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
19.46 | 62.17B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.11 | 47.95B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.93 | 43.67B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.43 | 32.41B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.89 | 23.24B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-23 | Eingeleitet | Oppenheimer | Outperform |
| 2026-09-09 | Eingeleitet | Leerink Partners | Outperform |
| 2026-02-09 | Hochstufung | UBS | Neutral → Buy |
| 2026-01-16 | Hochstufung | Argus | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Zacks Investment Research
An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan
Lumen Technologies, Inc. Common Stock (LUMN) Stock Forecasts - Yahoo! Finance Canada
Pacira BioSciences jumps 44% after Viatris agre... - Pluang
Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com
Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com
Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart
Why Pacira BioSciences Skyrocketed Today - The Motley Fool
Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com India
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom
VTRS vs. AVTR: Which Stock Is the Better Value Option? - Zacks Investment Research
Should Value Investors Buy Viatris (VTRS) Stock? - Zacks Investment Research
Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? - Zacks Investment Research
Lumen Technologies, Inc. Common Stock (LUMN) stock price, news, quote and history - Yahoo Finance UK
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com Nigeria
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com South Africa
Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com UK
Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? - Zacks Investment Research
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - Zacks Investment Research
Viatris (NasdaqGS:VTRS) Stock Forecast & Analyst Predictions - Simply Wall Street
Viatris Inc. (VTRS) stock price, news, quote and history - Yahoo Finance UK
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - TradingView
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 - TradingView
Here's Why Viatris (VTRS) is a Strong Value Stock - Eastern Progress
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Here's Why Viatris (VTRS) is a Strong Momentum Stock - Eastern Progress
Viatris, Long Chau launch lipid disorder management campaign - VnExpress International
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha
VTRS - Finviz
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan
Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - marketscreener.com
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews
Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Viatris Inc. (VTRS) Stock Analysis: Exploring Its 13% Upside Potential And Dividend Appeal - DirectorsTalk Interviews
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough? - Yahoo Finance
Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overv - GuruFocus
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score - GuruFocus
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Exploring a 13.36% Potential Upside Amidst Mixed Financial Signals - DirectorsTalk Interviews
Viatris' China Policy Concerns Overstated, UBS Says - Moomoo
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viatris Inc-Aktie (VTRS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Paul Campbell | Officer |
Jun 25 '26 |
Proposed Sale |
16.17 |
50,076 |
809,678 |
0 |
| Campbell Paul | See Remarks |
Jun 25 '26 |
Sale |
16.17 |
50,076 |
809,784 |
316,212 |
| Le Goff Corinne | Chief Commercial Officer |
Apr 15 '26 |
Option Exercise |
0.00 |
42,988 |
0 |
122,558 |
| Campbell Paul | See Remarks |
Mar 23 '26 |
Sale |
13.28 |
21,350 |
283,539 |
366,288 |
| Paul Campbell | Officer |
Mar 23 '26 |
Proposed Sale |
13.28 |
21,350 |
283,508 |
0 |
| MARK RICHARD A | Director |
Mar 06 '26 |
Option Exercise |
0.00 |
24,835 |
0 |
116,145 |
| Campbell Paul | See Remarks |
Mar 06 '26 |
Option Exercise |
0.00 |
28,974 |
0 |
398,956 |
| Smith Scott Andrew | Chief Executive Officer |
Mar 06 '26 |
Option Exercise |
0.00 |
130,701 |
0 |
1,374,576 |
| HIGGINS MELINA E | Director |
Mar 06 '26 |
Option Exercise |
0.00 |
24,835 |
0 |
146,048 |
| Groothuis Leo Frans | Director |
Mar 06 '26 |
Option Exercise |
0.00 |
24,835 |
0 |
63,567 |
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):